Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000151437
Ethics application status
Approved
Date submitted
28/01/2016
Date registered
9/02/2016
Date last updated
11/01/2017
Type of registration
Retrospectively registered

Titles & IDs
Public title
A Phase II study:
Haematopoietic Stem Cell Transplantation for highly active
treatment resistant multiple sclerosis .
Scientific title
A Phase II study:
Haematopoietic Stem Cell Transplantation for highly active
treatment resistant multiple sclerosis .
Secondary ID [1] 288507 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing Remitting Multiple Sclerosis 297449 0
Condition category
Condition code
Neurological 297637 297637 0 0
Multiple sclerosis
Inflammatory and Immune System 297638 297638 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Patients are assessed using inclusion and exclusion criteria, specific for the highly active, treatment resistant multiple sclerosis in order to determine whether they are eligible for an Autologous Stem cell transplant. If eligible, all patients are given intravenous Cyclophosphamide 2g/m2 as per standard practice followed by G-CSF 10mcg/kg for the next 10-12 days until the following Monday when stem cells are collected by taking 150-200mls of blood which is processed in the laboratory. Minimum target CD34+ stem cell collection will be 2 x 10^6/kg.
Patients will be admitted into hospital for their autologous stem cell transplant within 4-8 weeks of stem cell collection based on speed of laboratory processing to produce transplant cells. Patients will then undergo chemo-immunotherapy.
with BEAM therapy combined with Horse ATG (Atgam). This includes intravenous administration of all the following agents carmustine 300mg/m2 on Day -6; then cytosine arabinoside 200mg/m2 /day and etoposide 200mg/m2 /day on Days -5, -4, -3, -2; then Melfalan 140mg/m2 on Day -1. Reinfusion of stem cells occurs on Day 0. This is followed by intravenous methylprednisolone 5mg/Kg /day and intravenous horse antithymocyte globulin 20mg/Kg /day on Days +1 and +2.

Standard supportive measures including hydration, antiemetics, and antimicrobial prophylaxis are followed as per institutional protocols.
Intervention code [1] 293746 0
Treatment: Other
Intervention code [2] 293747 0
Treatment: Drugs
Comparator / control treatment
Uncontrolled
Control group
Uncontrolled

Outcomes
Primary outcome [1] 297178 0
Safety, as measured by transplant related mortality (TRM) by day 100. This is defined as death up to 100 days post transplant, not due to the original disease following review of the medical record.
Timepoint [1] 297178 0
Day 100 post transplant
Secondary outcome [1] 320249 0
Efficacy of HSCT in highly active multiple sclerosis that is refractory to standard therapies. This will be assessed using standardised clinical and laboratory criteria, including MRI and EDSS.
Timepoint [1] 320249 0
6months, 12months then yearly up to 5 years post transplant

Eligibility
Key inclusion criteria
Adequate organ function as measured by: Cardiac LV Ejection Fraction greater than 45%, total Lung Capacity greater than 60%, Pulmonary artery pressure less than 50mmHg, DLCO greater than or equal to 50%.
Negative serology for HBV, HCV and HIV.
Negative pregnancy test.
Able to provide informed consent and the absence of mental and cognitive deficits which can interfere with the capability of providing the informed consent.
Absence of severe chronic infection.

Specific Inclusion Criteria for multiple sclerosis
Age between 18-55
EDSS between 2.5-5.5
10 years or less since first treated for MS
And meets criteria (below) on both clinical and MRI grounds, for highly active MS within the past 2 years despite ongoing use of a PBS approved therapy
Clinical
i) a minimum of at least 1 severe relapse with an increase in EDSS of 1 (or 0.5 for those with pre relapse EDSS of 5.5 or above)
in motor, cerebellar or brain stem deficit (or documented changes in neurological examination consistent with these magnitudes)
and/or
ii) incomplete recovery from clinically significant relapses

MRI
i. at least one gadolinium-positive (Gd+) lesion of diameter 3 mm or greater on MRI within the past 6 months.
or
ii. accumulation of at least 0.3 T2 lesions/month on two consecutive MRIs 6–12 months apart.

Previous Treatment with Nataluzimab is allowed but a minimum of 6 months MUST have elapsed since completion of treatment.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Progressive forms of multiple sclerosis with no evidence of recent disease activity on MRI.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
open label
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
15/01/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
20
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 5202 0
Austin Health - Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 12664 0
3084 - Heidelberg

Funding & Sponsors
Funding source category [1] 292774 0
Hospital
Name [1] 292774 0
Austin Health
Country [1] 292774 0
Australia
Primary sponsor type
Hospital
Name
Austin Health
Address
145 Studley Road
Heidelberg Vic 3084
Country
Australia
Secondary sponsor category [1] 291561 0
None
Name [1] 291561 0
N/A
Address [1] 291561 0
N/a
Country [1] 291561 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 294269 0
Austin Health
Ethics committee address [1] 294269 0
Ethics committee country [1] 294269 0
Australia
Date submitted for ethics approval [1] 294269 0
02/03/2015
Approval date [1] 294269 0
19/06/2015
Ethics approval number [1] 294269 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 63126 0
Prof Richard Macdonell
Address 63126 0
Austin Health
145 Studley Road
Heidelberg Vic 3084
Country 63126 0
Australia
Phone 63126 0
+61 3 9496 3705
Fax 63126 0
+61 3 9496 2153
Email 63126 0
[email protected]
Contact person for public queries
Name 63127 0
Richard Macdonell
Address 63127 0
Austin Health
145 Studley Road,
Heidelberg Vic 3084
Country 63127 0
Australia
Phone 63127 0
+61 3 9496 3705
Fax 63127 0
+61 3 9496 2153
Email 63127 0
[email protected]
Contact person for scientific queries
Name 63128 0
Richard Macdonell
Address 63128 0
Austin Health
145 Studley Road
Heidelberg Vic 3084
Country 63128 0
Australia
Phone 63128 0
+61 3 9496 3705
Fax 63128 0
+61 3 9496 2153
Email 63128 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.